Methods of treating disease with levoketoconazole
Patent standing
- Legal status
- None recorded
- Granted
- 1 Jun 2021
- Validity challenges
- None recorded
- Licences recorded
- None recorded
Case record
- Patents involved
- US11020393B2US11278547B2US12377096B2US11903940B2
- Case no.
- 2:26-cv-02929
- Verdict cause
- Infringement action
- Court
- D.N.J.
- Court level
- District Court
- Case region
- New Jersey
- Chief judge
- None recorded
- Trial level
- First instance
- Filed – Closed
- 20 Mar 2026 – 8 Jun 2026
- Duration
- 80 days
- Basis of termination
- Case Consolidated
- Products & marks
- RECORLEV® (levoketoconazole) 150 mg tablets · levoketoconazole tablets, oral, 150 mg per tablet
Source: Patsnap Litigation Data. Case 2:26-cv-02929, United States District Court for the District of New Jersey.
Open this record in Eureka
Patsnap Eureka
Check this patent against your own product
Prior art, claim scope, infringement exposure and design-around routes. Every answer cites the records behind it.
Get an FTO claim chart10,000 free credits to start
US11020393B2
Assess invalidity risk
- 01Ranked prior artEvery hit source-linked
- 02Claim-level comparisonAgainst your own product
- 03Legal statusAcross 174 jurisdictions
Methods of treating disease with levoketoconazole
Patent standing
- Legal status
- None recorded
- Granted
- 22 Mar 2022
- Validity challenges
- None recorded
- Licences recorded
- None recorded
Also asserted in this case
2 moreThe docket lists 4 asserted patents. Full bibliographic detail, drawings and prosecution history for the remaining 2 asserted patents are one query away in Eureka.
Source: Patsnap patent data + case record. Bibliographic fields and drawings reproduced from the published patent document.
Break down the claims
Parties of record
Plaintiff
Xeris Pharmaceuticals, Inc.
- Core tech
- Not recorded
- Counsel
- Charles H. Chevalier
- Firm
- Fbt Gibbons LLP
Defendant
Sandoz, Inc.
- Core tech
- Not recorded
- Counsel
- Eric I. Abraham · Kristine L. Butler
- Firm
- Hill Wallack LLP
Counsel of record
| Attorney | For | Role |
|---|---|---|
| Charles H. Chevalier | Xeris Pharmaceuticals, Inc. | Plaintiff |
| Eric I. Abraham | Sandoz, Inc. | Defendant |
| Kristine L. Butler | Sandoz, Inc. | Defendant |
Source: case record + Patsnap company data. Attorney names appear as recorded in the docket.
Compare both portfolios
Basis of termination
From the record · verbatim"WHEREFORE, all counsel who have made their appearances, including pro hac vice admission, in Civil Action No. 2:26-cv-2929 shall be deemed to be admitted in the consolidated action, Civil Action No. 2:26-2044, and shall receive notices of electronic filings in the consolidated action."
Case 2:26-cv-02929 · D.N.J. · closed 8 June 2026
Source: case record, verbatim. The quoted paragraph is the basis-of-termination text as filed.
Related cases
Three questions this record usually leads to. Each one runs against the full litigation and patent corpus, and cites what it finds.
Frequently asked questions
What is case 2:26-cv-02929?
2:26-cv-02929 is a patent infringement action brought by Xeris Pharmaceuticals, Inc. against Sandoz, Inc., filed on 20 Mar 2026 in the United States District Court for the District of New Jersey. The case closed on 8 June 2026.
Which patents were asserted in 2:26-cv-02929?
US11020393B2 (“Methods of treating disease with levoketoconazole”), assigned to XERIS PHARMACEUTICALS, INC.; US11278547B2 (“Methods of treating disease with levoketoconazole”), assigned to XERIS PHARMACEUTICALS, INC.; US12377096B2 (“Methods of treating disease with levoketoconazole”), assigned to XERIS PHARMACEUTICALS, INC.; US11903940B2 (“Methods of treating disease with levoketoconazole”), assigned to XERIS PHARMACEUTICALS, INC.. The record also lists RECORLEV® (levoketoconazole) 150 mg tablets and levoketoconazole tablets, oral, 150 mg per tablet.
How was case 2:26-cv-02929 terminated?
The recorded basis of termination is case consolidated. The termination text reads: "WHEREFORE, all counsel who have made their appearances, including pro hac vice admission, in Civil Action No. 2:26-cv-2929 shall be deemed to be admitted in the consolidated action, Civil Action No. 2:26-2044, and shall receive notices of electronic filings in the consolidated action."
How long did case 2:26-cv-02929 take?
80 calendar days, from filing on 20 Mar 2026 to closure on 8 June 2026.
Who were the attorneys and the judge in 2:26-cv-02929?
Charles H. Chevalier is recorded as counsel for plaintiff Xeris Pharmaceuticals. Eric I. Abraham and Kristine L. Butler appear for defendant Sandoz.
Answers reproduce fields from the case record for 2:26-cv-02929 and do not constitute legal advice.
Ask your own question
Browse related dockets
Disclaimer. This page reproduces publicly available court docket data for case 2:26-cv-02929 and is provided for general information and reference only. It is not legal advice and must not be relied upon as such.
Docket data has limits. Records are drawn from a snapshot and may lag the live docket. Sealed filings, amended complaints, counterclaims and post-closure motions may not be reflected. Party names, attorney names and firm affiliations are reproduced as recorded and may contain omissions. Where a field is absent from the record, this page marks it as not recorded rather than inferring a value.
No characterisation of the parties or the outcome. This page reports what the record contains. Nothing here should be read as an assertion that any party infringed, that any patent is valid or invalid, that any settlement occurred, or that any party prevailed.
No FTO or validity opinion. Nothing on this page constitutes a freedom-to-operate, novelty, validity or infringement opinion. Any decision touching a live patent dispute should be verified independently and reviewed with qualified patent counsel.